PMID- 9631306
OWN - NLM
STAT- MEDLINE
DCOM- 19980820
LR  - 20191102
IS  - 1083-4389 (Print)
IS  - 1083-4389 (Linking)
VI  - 3
IP  - 2
DP  - 1998 Jun
TI  - Helicobacter pylori and peptic ulcer disease therapies: a survey of 
      gastroenterologists in Israel.
PG  - 93-6
AB  - BACKGROUND: Eradication of Helicobacter pylori has become a therapeutic option in 
      the treatment of patients with peptic ulcer disease. The aim of this study was to 
      evaluate the current management strategies of Israeli gastroenterologists in the 
      diagnosis and treatment of H. pylori-related peptic ulcer disease, 14 years after 
      the discovery of H. pylori. MATERIALS AND METHODS: A questionnaire was mailed to 
      all specialists in gastroenterology, members of the Israel Gastroenterological 
      Association (IGA). Replies were received from 60% of Israel Board-certified 
      gastroenterology specialists. RESULTS: Over 89% of the gastroenterologists 
      (89.1%) noted that they recommend anti-H. pylori treatment. 94.5% said that they 
      treat duodenal ulcer in the first presentation with anti-H. pylori medication and 
      75% said that they do so in cases of recurrent duodenal ulcer. According to the 
      replies received, there is a strong consensus towards triple treatment as the 
      favored anti-H. pylori treatment; no one noted the use of dual treatment. 
      Seven-day triple treatment was prescribed by 83.6% of the gastroenterologists who 
      responded. Of these, the great majority, 89.1%, stated that they use proton pump 
      inhibitors (PPI) in combination with any two of the following antibiotics: 
      metronidazole (47.3%), tinidazole (29.1%), clarithromycin (61.8%), and 
      amoxicillin (40%). CONCLUSION: At the time of the survey, most Israel 
      Board-certified gastroenterology specialists prescribed triple anti-H. pylori 
      treatment of one-week's duration.
FAU - Fireman, Z
AU  - Fireman Z
AD  - Gastroenterology Department, Hillel Yaffe Medical Center, Hadera, Israel. 
      fireman@post.tau.ac.il
FAU - Segal, A
AU  - Segal A
FAU - Moshkowitz, M
AU  - Moshkowitz M
FAU - Kopelman, Y
AU  - Kopelman Y
FAU - Sternberg, A
AU  - Sternberg A
LA  - eng
PT  - Journal Article
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Penicillins)
RN  - 0 (Proton Pump Inhibitors)
RN  - 033KF7V46H (Tinidazole)
RN  - 140QMO216E (Metronidazole)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Amoxicillin/pharmacology/therapeutic use
MH  - Anti-Bacterial Agents/pharmacology/therapeutic use
MH  - Clarithromycin/pharmacology/therapeutic use
MH  - Health Care Surveys
MH  - Helicobacter pylori/*drug effects
MH  - Humans
MH  - Israel
MH  - Metronidazole/pharmacology/therapeutic use
MH  - Penicillins/pharmacology/therapeutic use
MH  - Peptic Ulcer/*microbiology/*therapy
MH  - Proton Pump Inhibitors
MH  - Tinidazole/pharmacology/therapeutic use
EDAT- 1998/06/19 00:00
MHDA- 1998/06/19 00:01
CRDT- 1998/06/19 00:00
PHST- 1998/06/19 00:00 [pubmed]
PHST- 1998/06/19 00:01 [medline]
PHST- 1998/06/19 00:00 [entrez]
AID - 10.1046/j.1523-5378.1998.08032.x [doi]
PST - ppublish
SO  - Helicobacter. 1998 Jun;3(2):93-6. doi: 10.1046/j.1523-5378.1998.08032.x.